Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug

Key Takeaways

• Ascletis Pharma has completed enrollment of 100 participants in its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for diabetes
• ASC30 represents a potential breakthrough as a once-daily oral tablet alternative to current injectable GLP-1 treatments
• Topline efficacy and safety data from the U.S. Phase II study are expected in the third quarter of 2026

---

HONG KONG - Ascletis Pharma Inc. (HKEX: 1672) announced April 27, 2026, the completion of patient enrollment in its Phase II clinical trial evaluating ASC30, an investigational oral small molecule GLP-1 receptor agonist for diabetes treatment.

Study Details and Significance

The 13-week U.S. Phase II study (NCT07321678) enrolled 100 participants with diabetes to evaluate the efficacy, safety, and tolerability of ASC30 as a once-daily oral tablet. This milestone represents a significant step forward in developing what could become the first oral alternative to currently available injectable GLP-1 receptor agonists.

Market Impact and Innovation

ASC30’s oral formulation addresses a major limitation of existing GLP-1 treatments, which require injection and can deter patient compliance. The global GLP-1 receptor agonist market has experienced explosive growth, driven by drugs like Ozempic and Mounjaro, but an effective oral option could dramatically expand patient access and market penetration.

The completion of enrollment demonstrates Ascletis’s ability to execute clinical trials in the competitive diabetes space, where pharmaceutical giants are racing to develop next-generation treatments.

Timeline and Next Steps

Ascletis expects to report topline data from the Phase II study in the third quarter of 2026. These results will be crucial in determining whether ASC30 can match the efficacy of injectable GLP-1 treatments while maintaining an acceptable safety profile.

Successful Phase II results could position Ascletis for partnerships with larger pharmaceutical companies or advancement to Phase III trials, potentially accelerating the path to market for this novel oral diabetes treatment.

Investment Implications

For Ascletis shareholders, the enrollment completion represents progress toward a potentially transformative asset. However, investors should note that Phase II trials carry inherent risks, and positive results are not guaranteed. The diabetes treatment market’s size and growth trajectory make ASC30 a high-stakes development program for the Hong Kong-listed biotech company.

---

Frequently Asked Questions

What makes ASC30 different from existing diabetes treatments?

ASC30 is an oral GLP-1 receptor agonist taken as a once-daily tablet, unlike current GLP-1 treatments that require injection. This could significantly improve patient convenience and treatment adherence.

When will ASC30 be available to patients?

ASC30 is still in Phase II trials with results expected in Q3 2026. If successful, the drug would need to complete Phase III trials and regulatory approval, likely taking several more years before potential market availability.

How does Ascletis compare to other companies developing oral GLP-1 drugs?

Several pharmaceutical companies are racing to develop oral GLP-1 treatments. Ascletis’s ASC30 is one of multiple candidates in clinical development, competing with programs from larger pharmaceutical companies with more resources.